AstraZeneca stock drops 9% as heart drug trial fails to meet its primary goal

One press release.

One trial result.

$18 billion wiped off a pharma giant before lunch.

Meet Wainua.

AstraZeneca's bet on treating a rare, brutal heart condition called transthyretin-mediated amyloid cardiomyopathy.

In plain English: misfolded proteins slowly clog the heart muscle.

About 500,000 people worldwide live with it.

The trial ran for 140 weeks.

The goal was simple — fewer deaths, fewer heart emergencies, compared to placebo.

Wainua didn't hit it.

📉 The market didn't wait for explanations

Shares fell as much as 9% in London.

Worst single-day drop since March 2020.

Yes — the Covid crash.

That's the company AstraZeneca is being compared to today.

Here's what makes it sting more:

🧪 AstraZeneca was "very confident" going in, per a Jefferies analyst
💊 The drug is already approved for a different condition — nerve damage from the same protein disorder
🎯 This trial was meant to expand it into cardiology, a much bigger market
🏢 Analysts say the $80 billion 2030 sales target isn't dead — just dented

This is the uncomfortable truth about pharma.

Years of R&D. Billions in spend. Thousands of patients enrolled.

All of it can come down to a single readout.

Confidence isn't data.

Investors had priced in success.

They weren't ready for a miss.

AstraZeneca still has a massive pipeline.

Wainua still works for its original approved use.

But the cardiology dream — the bigger prize — just got harder to reach.

Sometimes the scariest number in pharma isn't the price of the drug.

It's the p-value that didn't cross the line.

That's all for now!